ACE OncoCast
The official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
Episodes
46 episodes
Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2)
Natalia Carballo, MDMD Anderson Cancer Center MadridMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune che...
•
Season 11
•
Episode 2
•
4:10
Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (1 of 2)
Félix Guerrero-Ramos, MD, PhD, FEBUHospital Doce de OctubreMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting im...
•
Season 11
•
Episode 2
•
12:33
Expert Interview of Specialist Insights in Urothelial Cancer: Molecular Pathology and Biology of Urothelial Cancer
Francisco X. Real, MD, PhDNational Cancer Research CenterMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immun...
•
Season 11
•
Episode 1
•
15:17
Expert Interview of Specialist Insights in Urothelial Cancer: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer
Enrique Grande, MD, MSc, PhDMD Anderson Cancer Center MadridMadrid, SpainThe therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting im...
•
Season 11
•
Episode 3
•
24:54
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 3
Episode 3:Panel Discussion & Pearls for PracticeAristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhDThe increasing availability of treatment options in the firs...
•
Season 10
•
Episode 3
•
21:33
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 2
Episode 2: Case 1: Second-line and salvage treatment options after maintenance immunotherapy Case 2: Second-line and salvage treatment options after platinum-based chemotherapyKate Smith, MBBS, MRCP, MD, PhD
•
Season 10
•
Episode 2
•
20:58
Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 1
Episode 1: Opening & Keynote Speech: Second-line and salvage treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC)Philippe Barthélémy, MD, PhDThe increasing a...
•
Season 10
•
Episode 1
•
21:41
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 3
Episode 3: Panel Discussion & Pearls for PracticeFernando Maluf, MD, PhD, Enrique Grande, MD, MSc, PhD and Joachim Chan, BSc, MBBS, MRCP, FRCR, MDThe therapeutic landscape of unresectable locally advanced or ...
•
Season 9
•
Episode 3
•
22:41
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 2
Episode 2: Case 1: First-line treatment with maintenance immunotherapy for a platinum-eligible patient Case 2: First-line treatment with mono-immunotherapy for a cisplatin-ineligible patientJoachim Chan, BSc, MBBS,...
•
Season 9
•
Episode 2
•
23:41
Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 1
Episode 1: Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC)Enrique Grande, MD, MSc, PhDThe therapeutic landscape of ...
•
26:44
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 4: Novel Drugs in Development
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armame...
•
Season 8
•
Episode 1
•
24:53
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 3: Second/subsequential Treatment Decision-making
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armame...
•
Season 8
•
Episode 3
•
16:43
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 1: First-line Treatment Decision-making
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armame...
•
Season 8
•
Episode 2
•
14:25
Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 2: First-line Maintenance Treatment Decision-making
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armame...
•
Season 8
•
Episode 4
•
20:43
Expert Interview: Frequently Asked Questions (FAQs) for Second Line (2L) and Salvage Treatments
There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. In recent years, ICIs have predominantly repl...
•
Season 8
•
Episode 4
•
10:50
Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC)
Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidisciplinary team (MDT), with c...
•
Season 8
•
Episode 2
•
13:53
Expert Interview: Frequently Asked Questions (FAQs) for Non Muscle Invasive Bladder Cancer (NMIBC)
About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmet...
•
Season 8
•
Episode 1
•
7:22
Expert Interview: Frequently Asked Questions (FAQs) for First Line (1L) Treatment Decision making
Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving development of immunotherapy in the first-l...
•
Season 8
•
Episode 1
•
17:07
Personalized therapy in SCLC: Promises and challenges
In the third and final podcast on extensive-stage SCLC, the experts discuss ongoing trials, as well as potential predictive biomarkers of response, and the problem of tumor plasticity.
•
Season 7
•
Episode 3
•
9:52
Closer look at the biology of SCLC and molecular subtypes
In the second podcast on extensive-stage SCLC, the experts examine the biology of SCLC and discuss the molecular subtypes, which have distinct therapeutic vulnerabilities.
•
Season 7
•
Episode 2
•
10:58
Current standard of care for ES SCLC
In this first of three podcasts on extensive-stage SCLC, the experts discuss the management of patients with relapsed SCLC based on current evidence and guidelines.
•
Season 7
•
Episode 1
•
16:43
Second-line and salvage treatments for metastatic urothelial cancer
In this final episode of our podcast exploring the role of immunotherapy in advanced urothelial cancer, Dr Tom Powles and Dr Aristotelis Bamias discuss the treatment options for patients after first-line or maintenance immunotherapy, including ...
•
Season 6
•
Episode 3
•
10:09
First-line treatment of advanced metastatic urothelial cancer
In the first of three podcasts exploring the role of immunotherapy in advanced urothelial cancer, genitourinary cancer experts Dr Tom Powles and Dr Aristotelis Bamias discuss the latest evidence-based treatment strategies for patients with adva...
•
Season 6
•
Episode 2
•
14:27